MEDTECH

Ligand Pharmaceuticals Selects Landing AI's LandingLens Visual Inspection Software Platform to Enhance the Antibody Discovery Platforms

Ligand Pharmaceuticals | July 29, 2021

Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions.

The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wide range of complex biological assays, possibly increasing the output of antibodies with desired characteristics in less time.

"Landing AI, led by world-renowned AI pioneer Andrew Ng, is a proven and trusted partner in enabling their clients to achieve the business value of computer vision," says Bob Chen, Ph.D., Ligand Pharmaceuticals' Director, Systems Engineering. "We selected Landing AI because of its unique data-centric approach, which puts collecting high-quality data at the core of AI development. Notably, the LandingLens software platform includes plenty of data preparation tools and features that enable us to create reliable and consistent datasets that we can iterate on over time to improve our existing AI systems continuously."

"Deep learning and AI have emerged as strong technologies for enabling a wide range of vision-based applications. We are happy to be working with Ligand Pharmaceuticals and are dedicated to providing the best tools to assist our customers in unlocking the promise of AI, "said John Reuter, Landing AI's Vice President of Sales.

About Ligand Pharmaceuticals
Ligand is a revenue-generating biopharmaceutical company that focuses on creating or acquiring technologies that aid pharmaceutical companies in discovering new medicines. Ligand's business strategy adds value to stockholders by offering a diverse portfolio of biotech and pharmaceutical product revenue streams backed by an efficient and low corporate cost structure. Ligand's goal is to provide investors with the chance to participate in the biotech industry's promise through a profitable, diversified, and lower-risk business than a typical biotech firm. Ligand's business strategy is built on what the company specializes in drug discovery, early-stage drug development, product reformulation, and partnering. In addition, Ligand collaborates with other pharmaceutical firms to capitalize on their capabilities (late-stage development, regulatory management, and commercialization) to generate revenue.

About AI Landing
Using enablement tools, Landing AI enables clients to realize the business and operational benefits of computer vision. LandingLens, the company's main product, is an enterprise MLOps system that enables end-to-end processes for developing, iterating, and deploying AI-powered visual inspection solutions. As data quality is important to the achievement of production AI systems, LandingLens includes plenty of specially designed data preparation tools and processes to assist users in achieving optimum data accuracy and consistency. Dr. Andrew Ng, the co-founder of Coursera, former chief scientist of Baidu, and founding lead of Google Brain, founded Landing AI, guided by a data-centric AI approach, and is uniquely positioned to help companies successfully move their AI projects from proof-of-concept to full-scale production.

Spotlight

This infographics related ton the plant science in biotechnology.

Spotlight

This infographics related ton the plant science in biotechnology.

Related News

CELL AND GENE THERAPY

Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars

Biocytogen | June 23, 2021

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, the organization autonomously created mouse stages for completely human neutralizer disclosure, RenMab® and RenLite®, that have free protected innovation rights. With the execution of these stages, Biocytogen has advanced from an agreement research association (CRO) into a global biotechnology organization with aptitude crossing the whole cycle of new drug R&D, including immune response drug target check, high-throughput single B cell counter acting agent revelation innovation, in vivo drug viability assessment utilizing adapted objective mice, and clinical turn of events. Genetic engineering of RenMab® and RenLite® mice has empowered the integration of Biocytogen's innovative qualities into a one of a kind enormous scope R&D plan for the revelation of helpful antibodies, a drive named the RenMice HiTS Platform. The HiTS Platform means the organization's obligation to finish high-productivity counter acting agent revelation and in vivo drug viability screening of in excess of 1,000 neutralizer targets in the following not many years, zeroing in on the disclosure of first-in-class and top tier drug targets. Through the ID of immune response drives that have been confirmed for adequacy in creature models, Biocytogen has set up co-improvement associations with in excess of twelve biotechnology and pharmaceutical organizations.

Read More

INDUSTRY OUTLOOK

Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, modified variant of IL-10 with enhanced durability properties over the naturally occurring wild-type cytokine. XT-150 is currently being evaluated in a Phase 2b study for moderate-to-severe pain caused by osteoarthritis of the knee, a Phase 1/2a study for peripheral neuropathic pain and a study for facet joint syndrome is expected to be initiated by end of year. While serving as milestones along a potential route to approval for each of these indications, the studies also provide valuable safety and efficacy data to guide future clinical development for additional indications currently in the IND-enabling stage. “We are proud to lead Xalud’s Series C financing and continue to support their efforts to build a leading gene therapy company that will address a significant unmet need in the field of chronic inflammatory diseases,” said Paul Manning, chief executive officer and chairman of PBM Capital. “Xalud has assembled an experienced leadership team, supported by diverse and distinguished strategic advisors, who have made strides in progressing their clinical programs and exploring additional indications with large potential.” About Xalud Therapeutics Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of IL-10, that addresses pathologic inflammation and pain.

Read More

MEDICAL

Sesen Bio Partners with Hikma Pharmaceuticals for the Registration and Commercialization of Vicineum

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") and different sorts of cancer in MENA. Vicineum, a privately managed combination protein, is Sesen Bio's lead product competitor presently in the subsequent phase of a Phase 3 enrollment preliminary for the treatment of high-hazard, BCG-unresponsive NMIBC. In December 2019, the Company started the BLA submission for Vicineum to the FDA under Rolling Review. Under the details of the understanding, Sesen Bio granted Hikma a exclusive license to register and commercialize Vicineum in all of the 19 MENA markets in a course of action foreseen to convey equivalent worth offer to the two players. Monetary terms of the arrangement are secret and incorporate a forthright installment to Sesen Bio, deals related achievement installments, and eminences on net deals in the locale for the term of the understanding. Sesen Bio holds full turn of events and commercialization rights for Vicineum for the treatment of NMIBC in the US and the remainder of the world barring Greater China and MENA.

Read More